Polyrizon partners with Clearmind to develop intranasal MEAI formulation
Go back to Polyrizon partners with Clearmind to develop intranasal MEAI formulation| (NASDAQ: CMND) | Delayed: 2.91 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.91 | 52 Week High | $ | |||
| Open | $2.87 | 52 Week Low | $ | |||
| Day High | $3.00 | P/E | N/A | |||
| Day Low | $2.84 | EPS | $ | |||
| Volume | 126,172 | |||||
| (NASDAQ: PLRZ) | Delayed: 12.80 -0.66 (4.9%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $13.46 | 52 Week High | $ | |||
| Open | $13.53 | 52 Week Low | $ | |||
| Day High | $13.92 | P/E | N/A | |||
| Day Low | $12.80 | EPS | $ | |||
| Volume | 26,430 | |||||

